Schubert & Co’s Guardant Health GH Stock Holding History

Schubert & Co’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	1505
2022 Q1	$0	Hold	2	–	–	﹤0.01%	1168
2021 Q4	$0	Buy	+2	New	+$207	﹤0.01%	1106

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Schubert & Co's GH Position: Q2 2022 in Review

Schubert & Co sold out of Guardant Health (GH) in Q2 2022, closing a stake of 2 shares.

Schubert & Co first reported a position in GH in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 332 funds tracked by Wall St. Rank hold GH as of Q2 2022.

Schubert & Co reported no remaining Guardant Health position as of Q2 2022 after selling out during the quarter.
Schubert & Co sold 2 Guardant Health shares in Q2 2022.
Schubert & Co first reported a position in Guardant Health in Q4 2021 and held it in 2 quarters.
Schubert & Co's Guardant Health position peaked at $0 in Q1 2022.
332 funds tracked by Wall St. Rank held Guardant Health as of Q2 2022.

Based on Schubert & Co's 13F filing for Q2 2022, filed 1 Aug 2022.